Overview
Updated 14 Jul 2026
Daniel J. DeAngelo, MD,PHD, is Chief, Division of Leukemia at Dana-Farber Cancer Institute, Boston, MA. The public record shows 933 publications with 38,550 citations (h-index 93), centered on Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Chronic Myeloid Leukemia Treatments. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 25 companies, 1 NIH-funded awards (2025–2025).
- Most recent indexed publication: 2026 · Cancer research communications
- Top research focus: Acute Myeloid Leukemia Research
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 25 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 56 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 362.
Clinical & industrytrials, payments and federal funding
Public positionssourced statements on record
- Co-chair emeritus
National Cancer Institute (NCI) Leukemia Steering Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗ - Member
NCCN Guidelines Committees (CML and ALL)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- SPARK-ALL: Calaspargase Pegol in Adults With ALL
Sponsor: Institut de Recherches Internationales Servier
InvestigatorPhase 2/PHASE3TerminatedNCT04817761 - Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
Sponsor: GlycoMimetics Incorporated
InvestigatorPhase 3TerminatedNCT03616470 - Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Sponsor: Alliance for Clinical Trials in Oncology
InvestigatorPhase 3RecruitingNCT03150693
Industry payments
Updated 14 Jul 2026
25 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Autolus IncProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- PFIZER INC.Program year20252 payments
NIH funding
Updated 14 Jul 2026
1 NIH research award on record, funded 2025–2025 per NIH RePORTER. The latest:
Congress activity
Updated 14 Jul 2026
229 congress contributions (2005–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- A phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity.
Science (New York, N.Y.)
2026
Most-cited worksby citation count (OpenAlex)
- 01
- 02Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia1,474 citations2017
- 03
- 04
- 05A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias1,127 citations2013
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
450 Brookline Avenue, Boston, MA 02215
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗
- BS
Chemistry, University of California, Berkeley
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗ - PhD
Molecular Genetics, Albert Einstein College of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗ - Internal Medicine Residency
Massachusetts General Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Clinical Fellowship
Hematology & Oncology, Brigham and Women's Hospital / Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Board Certified
Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
Editorial & leadership rolesjournal and society appointments
- Clinical Director
Adult Leukemia Program, Dana-Farber Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Medical Oncology Education Award
Dana-Farber Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗ - Lee Nadler Extra Mile Award
Dana-Farber Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗
Secondary affiliationsappointments beyond the home institution
- Attending Physician
Brigham and Women's Hospital
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗ - Member
Developmental Therapeutics and Leukemia Programs, Dana-Farber/Harvard Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicianresources.dana-farber.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/daniel-deangelo-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by otherswhere others cite or feature them
- Other
physicianresources.dana-farber.org/videos/daniel-deangelo-md-phd-on-a-novel-systemic-mastocytosis-sm-drug
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicianresources.dana-farber.org ↗ - X / Twitter
x.com/DanaFarber/status/1865941582647799921
- X / Twitter
x.com/OncLive/status/1853965525547917584
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Nikhil Munshi, MD
Dana-Farber Cancer Institute
- 1,801
- publications
- 152
- h-index
- 8
- trials
Patrick Wen, MD
Dana-Farber Cancer Institute
- 1,915
- publications
- 146
- h-index
- 27
- trials
Geoffrey Shapiro, MD
Dana-Farber Cancer Institute
- 2,055
- publications
- 116
- h-index
- 24
- trials
Irene Ghobrial, MD
Dana-Farber Cancer Institute
- 1,124
- publications
- 101
- h-index
- 16
- trials